Short Interest in Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Decreases By 42.1%

Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) saw a large decline in short interest in May. As of May 15th, there was short interest totaling 8,051 shares, a decline of 42.1% from the April 30th total of 13,895 shares. Based on an average daily volume of 28,212 shares, the short-interest ratio is presently 0.3 days. Currently, 0.1% of the shares of the stock are sold short.

Alterity Therapeutics Stock Down 0.9%

Shares of NASDAQ:ATHE traded down $0.04 on Tuesday, hitting $4.00. The stock had a trading volume of 8,419 shares, compared to its average volume of 23,723. The firm’s 50 day moving average price is $4.09 and its 200-day moving average price is $3.63. Alterity Therapeutics has a twelve month low of $2.66 and a twelve month high of $7.00.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ATHE. Zacks Research upgraded shares of Alterity Therapeutics to a “hold” rating in a research note on Thursday, February 12th. Weiss Ratings restated a “sell (e+)” rating on shares of Alterity Therapeutics in a research note on Monday, April 20th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Alterity Therapeutics stock. Citadel Advisors LLC purchased a new stake in Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 22,144 shares of the company’s stock, valued at approximately $83,000. Citadel Advisors LLC owned about 0.25% of Alterity Therapeutics as of its most recent SEC filing. 2.14% of the stock is currently owned by institutional investors and hedge funds.

Alterity Therapeutics Company Profile

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.